Full View

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations

S Wang, P Xing, K Yang, X Hao, D Ma, Y Mu… - Thoracic …, 2019 - Wiley Online Library
Background Afatinib is an irreversible ErbB family blocker that improves progression‐free
survival (PFS) of advanced EGFR‐mutant lung adenocarcinoma compared to …
被引用次数：12 相关文章

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations.

S Wang, P Xing, K Yang, X Hao, D Ma, Y Mu, J Li - Thoracic Cancer, 2019 - europepmc.org
Background Afatinib is an irreversible ErbB family blocker that improves progression-free
survival (PFS) of advanced EGFR-mutant lung adenocarcinoma compared to chemotherapy …

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations

S Wang, P Xing, K Yang, X Hao, D Ma, Y Mu… - Thoracic …, 2019 - search.proquest.com
Background Afatinib is an irreversible ErbB family blocker that improves progression‐free
survival (PFS) of advanced EGFR‐mutant lung adenocarcinoma compared to …
[HTML] nih.gov

[HTML][HTML] Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations

S Wang, P Xing, K Yang, X Hao, D Ma, Y Mu… - Thoracic Cancer, 2019 - ncbi.nlm.nih.gov
Background Afatinib is an irreversible ErbB family blocker that improves progression‐free
survival (PFS) of advanced EGFR‐mutant lung adenocarcinoma compared to …

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations

S Wang, P Xing, K Yang, X Hao, D Ma… - Thoracic …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Afatinib is an irreversible ErbB family blocker that improves progression-free
survival (PFS) of advanced EGFR-mutant lung adenocarcinoma compared to chemotherapy …

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations.

S Wang, P Xing, K Yang, X Hao, D Ma, Y Mu, J Li - Thoracic Cancer, 2019 - europepmc.org
Background Afatinib is an irreversible ErbB family blocker that improves progression-free
survival (PFS) of advanced EGFR-mutant lung adenocarcinoma compared to chemotherapy …